HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis
Authors
Keywords
-
Journal
PHARMACOGENOMICS JOURNAL
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-06
DOI
10.1038/s41397-019-0092-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association Between HLA genotypes and Oxcarbazepine-induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-Analysis
- (2018) Wimonchat Tangamornsuksan et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions
- (2018) Wimonchat Tangamornsuksan et al. JAMA Dermatology
- Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population
- (2018) Taisei Mushiroda et al. JAMA Neurology
- Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis
- (2018) Wimonchat Tangamornsuksan et al. PHARMACOGENOMICS JOURNAL
- Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity
- (2017) G. S. Ghattaoraya et al. International Journal of Immunogenetics
- Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes
- (2017) C F Spraggs et al. PHARMACOGENOMICS JOURNAL
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
- (2016) Martine Piccart-Gebhart et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials
- (2016) Yong Xin et al. Cancer Medicine
- Association of HLA-B*5701 Genotypes and Abacavir-Induced Hypersensitivity Reaction: A Systematic Review and Meta-Analysis
- (2015) Wimonchat Tangamornsuksan et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01
- (2015) Makoto Hirasawa et al. PLoS One
- Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review
- (2014) Yi Ling Teo et al. Expert Opinion on Drug Metabolism & Toxicology
- Prospective Validation ofHLA-DRB1*07:01Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury
- (2014) Daniel J. Schaid et al. JOURNAL OF CLINICAL ONCOLOGY
- Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations
- (2014) Faviel F. González-Galarza et al. NUCLEIC ACIDS RESEARCH
- Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience
- (2013) Bulent Cetin et al. Breast Care
- A systematic review of dual targeting in HER2-positive breast cancer
- (2013) Iben Kümler et al. CANCER TREATMENT REVIEWS
- Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Relationship Between theHLA-B*1502Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
- (2013) Wimonchat Tangamornsuksan et al. JAMA Dermatology
- Lapatinib-Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes
- (2012) C F Spraggs et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
- (2012) Paul E Goss et al. LANCET ONCOLOGY
- Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
- (2011) Ratchadaporn Somkrua et al. BMC Medical Genetics
- HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer
- (2011) Colin F. Spraggs et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib-induced hepatitis: A case report
- (2011) Stavros Peroukides WORLD JOURNAL OF GASTROENTEROLOGY
- Lapatinib for breast cancer: a review of the current literature
- (2010) Robyn J MacFarlane et al. Expert Opinion On Drug Safety
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
- HLA-B*5701 Screening for Hypersensitivity to Abacavir
- (2008) Simon Mallal et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now